食管癌BRCA1和β-tubulin Ⅲ mRNA表达与紫杉类耐药性的临床研究

姜维美; 叶维; 蒋华; 朱志霞

doi:10.3969/j.issn.1000-8179.20130617

食管癌BRCA1和β-tubulin Ⅲ mRNA表达与紫杉类耐药性的临床研究

Relationship of BRCA1 and β-tubulin Ⅲ mRNA expression with efficacy of taxanes for advanced esophageal carcinoma

摘要

摘要:
目的检测食管癌组织BRCA1、β-tubulin Ⅲ mRNA的表达，探讨与紫杉类耐药性的关系。
方法收集36例晚期食管癌组织标本，采用RTq-PCR方法检测组织中BRCA1、β-tubulin Ⅲ mRNA表达，分析二者与紫杉类药物耐药性的关系。
结果 BRCA1相对于内参基因β-actin的中位值为6.27；β-tubulin Ⅲ相对于内参基因β-actin的中位值为4.44。以中位值作为cutoff值，36例标本根据cutoff值分为低表达组和高表达组。BRCA1高表达组的有效率66.7%（12/18）稍高于低表达组55.6%（10/18），但二者差异无统计学意义（P=0.733）。β-tubulin Ⅲ低表达组的有效率83.3%（15/18）显著高于高表达组38.9%（7/18），差异有统计学意义（P=0.015）。
结论 BRCA1 mRNA表达水平与紫杉类药物敏感性差异无统计学意义。β-tubulin Ⅲ mRNA表达水平与紫杉类药物敏感性之间存在相关性。提示β-tubulin Ⅲ可以作为紫杉烷类药物在晚期食管癌中疗效的预测因子。

Abstract:
Objective To investigate the relationship of the mRNA expression of BRCA1 and β-tubulin Ⅲ with docetaxel-resistance in esophageal cancer.
Methods The genes BRCA1 and β-tubulin Ⅲ were determined at the mRNA level using RT-qPCR in 36 esophageal carcinoma specimens.
Results The mRNA expression of BRCA1 and β-tubulin Ⅲ was determined in the 36 tumor samples using RT-qPCR. The median BRCA1 mRNA expression level in relation to that of β-actin was 6.27. The median β-tubulin Ⅲ mRNA expression level in relation to that of β-actin was 4.44. The patients were divided into two groups using these cutoff values. The BRCA1 mRNA expression level was not correlated with the sensitivity of esophageal cancer patients to docetaxel (P=0.733). The response rate of the tumors with high β-tubulin Ⅲ expression was (38.9%), which is significantly lower than in patients with low β-tubulin Ⅲ expression (83.3%) (P=0.015).
Conclusion The β-tubulin Ⅲ expression levels in the tumor tissues were probably an important biomarker for the efficacy of docetaxel chemotherapy in esophageal cancer patients. Our study may provide new insights into taxane chemotherapy for advanced esophageal cancer patients.

HTML全文

参考文献(17)

施引文献

资源附件(0)